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1. INTRODUCTION {#jcla23189-sec-0005}
===============

Osteosarcoma (OS), which arises from primitive bone‐forming mesenchymal cells, is one of the most prevalent bone malignancies. It affects patients of all ages, particularly children and adolescents, accounting for approximately 56% of all pediatric bone tumors.[1](#jcla23189-bib-0001){ref-type="ref"}, [2](#jcla23189-bib-0002){ref-type="ref"} OS develops most commonly in areas where the bone is growing rapidly, such as the distal femur and proximal tibia. The typical presenting symptom is the onset of pain and swelling in the affected bone, and occasionally, patients present with pathologic fracture.[3](#jcla23189-bib-0003){ref-type="ref"} Approximately 20% of OS patients have clinically detectable metastases at diagnosis, which occurs most commonly in the lung.[4](#jcla23189-bib-0004){ref-type="ref"} With the introduction of chemotherapy in the 1970s, substantial improvement in long‐term survival has been achieved.[5](#jcla23189-bib-0005){ref-type="ref"} However, the prognosis of some OS patients is still poor due to the rapid progression and metastasis, and patients with metastatic disease showed much lower event‐free survival rate than that those with localized disease.[3](#jcla23189-bib-0003){ref-type="ref"} Therefore, early diagnosis of OS is critical for improving the therapeutic effect of patients.

Tumor markers have been widely used in clinical management for many cancers. They are of great value in many clinical aspects, such as screening early malignancy, diagnosis, therapeutic effect monitoring, and prognosis evaluation.[6](#jcla23189-bib-0006){ref-type="ref"} Regarding OS, serum alkaline phosphatase (ALP) is probably one of the most well‐known tumor markers. Numerous studies have shown that pre‐treatment serum ALP, as well as its changes during therapeutic process, is a critical prognostic indicator for chemotherapy response, skeletal and lung metastases, and survival of OS patients.[7](#jcla23189-bib-0007){ref-type="ref"}, [8](#jcla23189-bib-0008){ref-type="ref"}, [9](#jcla23189-bib-0009){ref-type="ref"}, [10](#jcla23189-bib-0010){ref-type="ref"} In addition, it has been known for a long time that OS patients often have higher serum ALP than normal subjects and patients with benign bone lesions, and ALP might help to diagnose OS initially. However, there were still a large part (\>40%) of OS patients with normal ALP levels, resulting in very low sensitivity for ALP in OS diagnosis.[10](#jcla23189-bib-0010){ref-type="ref"}

Some other clinical parameters have been identified and reported as potential tumor markers in OS besides ALP. For example, serum lactate dehydrogenase (LDH),[8](#jcla23189-bib-0008){ref-type="ref"}, [11](#jcla23189-bib-0011){ref-type="ref"} serum C‐reactive protein,[12](#jcla23189-bib-0012){ref-type="ref"} lymphocyte‐to‐monocyte ratio (LMR),[13](#jcla23189-bib-0013){ref-type="ref"} neutrophil‐to‐lymphocyte ratio (NLR), and platelet‐to‐lymphocyte ratio (PLR)[14](#jcla23189-bib-0014){ref-type="ref"} were also described as predictors of clinical prognosis in OS patients. However, the diagnostic performances of these clinical parameters to identify OS are largely unknown. Although some new indicators have been found to be elevated in OS patients,[15](#jcla23189-bib-0015){ref-type="ref"}, [16](#jcla23189-bib-0016){ref-type="ref"} their role in clinical diagnosis still needs further evaluation. Therefore, there is still no highly sensitive and specific markers to detect OS at the early stage at present.

In this study, we established diagnosis models of OS based on large‐scale clinical laboratory data and identify classifiers for different age groups that could differentiate individuals with OS from healthy individuals. Then, we determined whether these classifiers discriminated OS from primary benign bone lesions effectively. In addition, we investigated the performances of the established diagnostic classifiers for detection of small‐size and early‐stage OS. Finally, the capability of these classifiers to detect ALP‐negative OS was also evaluated.

2. MATERIALS AND METHODS {#jcla23189-sec-0006}
========================

2.1. Study population {#jcla23189-sec-0007}
---------------------

A total of 458 patients initially diagnosed with OS, and 312 healthy individuals who had undergone a medical examination in Peking University People\'s Hospital from September 2012 to July 2018 were included in this study. All samples were randomly divided into training cohort and validation cohort. The training cohort included 322 patients and 217 healthy individuals, while the validation cohort included 136 patients and 95 healthy individuals.

To test whether the classifier can discriminated OS from primary benign bone lesions, 228 patients with primary benign bone lesions, including 10 with simple bone cyst, 5 with aneurysmal bone cyst, 42 with osteoma, 10 with osteoid osteoma, 100 with giant cell tumor of bone, 19 with hemangioma, 29 with osteochondroma, and 13 with enchondroma, were also used as test set. All patients with OS and benign bone lesions were pathologically confirmed. This study was conducted according to the principles of the Declaration of Helsinki and approved by the Ethics Committee of Peking University People\'s Hospital. The requirement to obtain informed consent was waived because of the retrospective nature of the study.

The medical records of the included patients were reviewed, and hematological and biochemical test results before treatment were obtained. The clinicopathological characteristics, including age, gender, pathological fracture, clinical stage, pulmonary metastasis, tumor size, tumor location, preoperative chemotherapy, and Huvos grade, of OS patients were extracted. In addition, the hematological and biochemical test results of the medical examination in healthy individuals were obtained as well. A total of 43 common hematological and biochemical parameters, and three ratios which were reported to be associated with OS, including LMR, NLR, and PLR,[13](#jcla23189-bib-0013){ref-type="ref"}, [14](#jcla23189-bib-0014){ref-type="ref"} were included in this study (Table [S1](#jcla23189-sup-0005_TableS1-S10){ref-type="supplementary-material"}). The reference interval of serum ALP was that: 0‐15 y, 42‐390 U/L; 16‐18 y, 52‐171 U/L; \>19 y (male), 45‐125 U/L; 19‐49 y (female), 35‐100 U/L; \>50 y (female), 50‐135 U/L. Serum ALP below the upper limit of the reference interval was considered as ALP‐negative.

2.2. Feature selection and the establishment of the diagnostic classifiers {#jcla23189-sec-0008}
--------------------------------------------------------------------------

Logistic regression (LR) was performed with Python 3.7.3 to establish the diagnostic classifiers. As a statistical model, LR uses a logistic function to model a binary dependent variable and learns the coefficients of each feature. Features used to establish the diagnostic model were selected based on the training cohort. In each round of feature selection process, 70% of OS patients and health individuals in training cohort were randomly selected to build a logistic regression model based on all the 46 features. In order to eliminate the differences between features, we rescaled the data by applying *z*‐score transformation to each feature, which ensures that each feature obeys a standard normal distribution. Since our data have been standardized, the absolute value of the coefficients in the logistic regression model can reflect the importance of corresponding features. The above process was repeated 1000 times, and each time, the top‐10 ranked features were recorded. Finally, all the 46 features were ranked by their frequencies in the records and the top‐10 ranked features were selected to establish the diagnostic model. Analysis of the receiver operating characteristic (ROC) curves and the area under the ROC curves (AUC) were performed using Python 3.7.3.

2.3. Statistical analysis {#jcla23189-sec-0009}
-------------------------

All statistical analyses were carried out with GraphPad Prime 5.01 or SPSS software. The clinical parameters are expressed as mean ± standard deviation. Results between OS patients and healthy individuals were compared using student\'s *t* test for values that followed a Gaussian distribution, and using Mann‐Whitney *U* test for values that did not follow a Gaussian distribution. All the statistical tests were 2‐tailed. A *P* value \< .05 was considered statistically significant.

3. RESULTS {#jcla23189-sec-0010}
==========

3.1. Establishment of diagnostic classifiers for osteosarcoma {#jcla23189-sec-0011}
-------------------------------------------------------------

We collected 770 participants, including 458 OS patients and 312 healthy controls (HCs), and randomly divided into training cohort and validation cohort (Figure [S1](#jcla23189-sup-0001){ref-type="supplementary-material"}). For each cohort, participants were divided into two age groups: low ages (≤15 y) and high ages (\>15 y), because of the great difference in the reference interval of serum ALP between two age groups. The age and gender of patients with OS and HCs were well matched in each group (Table [S2](#jcla23189-sup-0005_TableS1-S10){ref-type="supplementary-material"}). Clinicopathological characteristics of OS patients in each group were displayed in Table [1](#jcla23189-tbl-0001){ref-type="table"}. A total of 46 clinical laboratory parameters (Table [S1](#jcla23189-sup-0005_TableS1-S10){ref-type="supplementary-material"}) were used to develop the diagnostic models.

###### 

Clinicopathological characteristics of included OS patients

  Clinical parameters         Training cohort   Validation cohort                  
  --------------------------- ----------------- ------------------- -------------- ---------------
  Gender                                                                           
  Male                        98                108                 41             46
  Female                      67                49                  28             21
  Age (Mean ± SD)             11.00 ± 3.02      25.36 ± 11.97       11.14 ± 2.88   25.78 ± 12.47
  Pathological fracture                                                            
  Yes                         15                9                   10             9
  No                          150               148                 59             58
  Clinical stage                                                                   
  I‐II                        121               127                 51             49
  III                         44                30                  18             18
  Pulmonary metastasis                                                             
  Yes                         40                22                  14             17
  No                          125               135                 55             50
  Tumor size                                                                       
  ≤6 cm                       83                93                  34             33
  \>6 cm                      58                49                  22             24
  NA                          24                15                  13             10
  Tumor location                                                                   
  Tibia/femur                 125               101                 52             43
  Elsewhere                   40                56                  17             24
  Preoperative chemotherapy                                                        
  Yes                         163               114                 65             55
  No                          2                 43                  4              12
  Huvos grade                                                                      
  I‐II                        94                67                  31             34
  III‐IV                      48                39                  25             12
  NA                          23                51                  13             21

Abbreviations: OS, osteosarcoma; NA, not available; SD, standard deviation.
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Classifiers were built for three age groups all ages (*C* ~os~), low ages (*C* ~los~), and high ages (*C* ~hos~), respectively. For each age group, top ten features were selected to build the diagnostic model (Figure [1](#jcla23189-fig-0001){ref-type="fig"}). Details of the feature selection process were described in the materials and methods section. Then, for each age group, the classifier was built with the training set on the top selected features. Notably, all included parameters showed statistically significant differences between OS patients and HCs (Tables [S3‐S5](#jcla23189-sup-0005_TableS1-S10){ref-type="supplementary-material"}).

![Importance matrix plot of logistic regression as described in Materials and Methods. The rankings of 46 clinical parameters for all ages (A), low ages (B), and high ages (C) were shown](JCLA-34-e23189-g001){#jcla23189-fig-0001}

The classifiers for all ages (*C* ~os~), low ages (*C* ~los~), and high ages (*C* ~hos~) were as follows. In order to make these classifiers easy to use, we reversed the z‐score to the actual value of each feature and derived the final formulas of these classifiers. If the value of the corresponding classifier was lower than 0.5, the detected sample was predicted as OS; otherwise as non‐OS.$$\begin{matrix}
{C_{\text{os}} = - 16.949 - 0.4604 \times \text{NE}\# + 0.6517 \times \text{MPV} - 0.0051 \times \text{ALP} - 0.0329} \\
{\times \text{LDH} + 0.0337 \times \text{HBD} + 0.0092 \times \text{CK} + 0.2345 \times \text{ALB} + 2.5718} \\
{\times \text{HDL}\_ C - 0.2579 \times \text{IP} - 0.0249 \times \text{LMR}} \\
 \\
\end{matrix}\begin{matrix}
{C_{\text{los}} = - 3.0437 - 10.2969 \times {\text{NE\textbackslash\%}\mspace{6mu}} + 0.6227 \times \text{MPV} - 0.1086 \times \text{GGT} - 0.0051} \\
{\times \text{ALP} + 0.0104 \times \text{CK} + 0.2508 \times \text{ALB} - 0.9695 \times \text{Glu} - 2.004} \\
{\times \text{IP} + 2.0102 \times A/G - 5.3642 \times \text{DBIL}/\text{TBIL}} \\
 \\
\end{matrix}\begin{matrix}
{C_{\text{hos}} = - 25.0011 + 10.0529 \times {\text{LY\textbackslash\%}\mspace{6mu}} + 19.9989 \times \text{BA}\# + 0.7464 \times \text{MPV} - 0.024} \\
{\times \text{ALP} - 0.0117 \times \text{LDH} + 0.0837 \times \text{TP} + 0.2004 \times \text{ALB} + 0.0414} \\
{\times \text{CRE} + 4.8913 \times \text{HDL}\_ C - 4.3709 \times \text{IP}} \\
 \\
\end{matrix}$$

(Annotations: The features in the above formulas represent their actual values. Units: NE\#, 10^9^/L; MPV, fL; ALP, U/L; LDH, U/L; HBD, U/L; CK, U/L; ALB, g/L; HDL_C, mmol/L; IP, mmol/L; GGT, U/L; Glu, mmol/L; BA\#, 10^9^/L; TP, g/L; CRE, μmol/L).

ROC analyses were conducted to evaluate the performances of these classifiers in the validation cohort. As shown in Figure [2](#jcla23189-fig-0002){ref-type="fig"}A and Table [2](#jcla23189-tbl-0002){ref-type="table"}, *C* ~os~ had an AUC 0.93 to discriminate all individuals with OS from HCs, and the accuracy, sensitivity, and specificity were 84.0%, 84.6%, and 83.2%, respectively. However, the AUC (0.69), accuracy (68.8%), sensitivity (83.1%), and specificity (48.4%) for ALP were much lower than those for *C* ~os~ in all ages. For low ages, the *C* ~los~ had an AUC 0.97 to discriminate relatively young individuals with OS from HCs, and the accuracy, sensitivity, and specificity were 88.5%, 85.5%, and 92.5%, respectively, which was also much better than ALP (AUC 0.66, accuracy 59.8%, sensitivity 76.8%, and specificity 37.7%) (Figure [2](#jcla23189-fig-0002){ref-type="fig"}B, Table [2](#jcla23189-tbl-0002){ref-type="table"}). For high ages, *C* ~hos~ had an AUC 0.98 to discriminate relatively old individuals with OS from HCs, and the accuracy, sensitivity, and specificity were 91.7%, 88.1%, and 97.6%, respectively, while the AUC (0.86), accuracy (81.7%), sensitivity (77.6%), and specificity (88.1%) for ALP was lower than those for *C* ~hos~ as well (Figure [2](#jcla23189-fig-0002){ref-type="fig"}C, Table [2](#jcla23189-tbl-0002){ref-type="table"}). Together, these results suggest that the performances of *C* ~os~, *C* ~los,~ and *C* ~hos~ were greater than that of ALP on OS diagnosis.

![Performance of *C* ~os~, *C* ~los,~ and *C* ~hos~ to detect osteosarcoma (OS) in the validation cohort. ROC curves were shown for distinguishing individuals with OS from healthy controls (HCs) in all ages (A), low ages (B), and high ages (C), respectively. Performance of *C* ~os~, *C* ~los,~ and *C* ~hos~ to discriminate OS from primary benign bone lesions in all ages (D), low ages (E), and high ages (F) was shown as well](JCLA-34-e23189-g002){#jcla23189-fig-0002}

###### 

Performance of *C* ~os~, *C* ~los~, *C* ~hos,~ and ALP for detection of osteosarcoma

                                                Accuracy % (95% CI)   Sensitivity % (95% CI)   Specificity % (95% CI)   PPV % (95% CI)      NPV % (95% CI)     PLR (95% CI)          NLR (95% CI)       DOR (95% CI)
  --------------------------------------------- --------------------- ------------------------ ------------------------ ------------------- ------------------ --------------------- ------------------ ------------------------
  Osteosarcoma vs healthy control                                                                                                                                                                       
  All ages                                                                                                                                                                                              
  *C* ~os~                                      84.0 (79.3‐88.7)      84.6 (78.5‐90.6)         83.2 (75.6‐90.7)         87.8 (83.6‐92.0)    79.0 (73.7‐84.3)   5.02 (3.19‐7.89)      0.19 (0.12‐0.28)   27.04 (13.28‐55.03)
  ALP                                           68.8 (62.9‐84.8)      83.1 (76.8‐89.4)         48.4 (38.4‐58.5)         69.8 (63.8‐75.7)    66.7 (60.6‐72.7)   1.61 (1.31‐1.99)      0.35 (0.23‐0.54)   4.61 (2.53‐8.42)
  ≤15 y                                                                                                                                                                                                 
  *C* ~los~                                     88.5 (82.9‐94.2)      85.5 (77.2‐93.8)         92.5 (85.3‐99.6)         93.7 (89.3‐98.0)    83.1 (76.4‐89.7)   11.33 (4.39‐29.22)    0.16 (0.09‐0.28)   72.28 (21.34‐244.78)
  ALP                                           59.8 (51.1‐68.5)      76.8 (66.9‐86.8)         37.7 (24.7‐50.8)         61.6 (53.0‐70.3)    55.6 (46.7‐64.4)   1.23 (0.96‐1.58)      0.61 (0.35‐1.07)   2.01 (0.91‐4.42)
  \>15 y                                                                                                                                                                                                
  *C* ~hos~                                     91.7 (86.6‐96.9)      88.1 (80.3‐95.8)         97.6 (93.0‐100.0)        98.3 (95.9‐100.0)   83.7 (76.7‐90.6)   36.99 (5.32‐256.99)   0.12 (0.06‐0.23)   302.38 (36.41‐2510.94)
  ALP                                           81.7 (74.4‐88.9)      77.6 (67.6‐87.6)         88.1 (78.3‐97.9)         91.2 (85.9‐96.5)    71.2 (62.6‐79.7)   6.52 (2.84‐14.99)     0.25 (0.16‐0.40)   25.65 (8.57‐76.79)
  Osteosarcoma vs primary benign bone lesions                                                                                                                                                           
  All ages                                                                                                                                                                                              
  *C* ~os~                                      87.6 (84.3‐91.0)      86.0 (80.2‐91.9)         88.6 (84.5‐92.7)         81.8 (77.9‐85.8)    91.4 (88.5‐94.3)   7.54 (5.22‐10.90)     0.16 (0.10‐0.24)   47.84 (25.38‐90.18)
  ALP                                           52.2 (47.1‐57.3)      97.8 (95.3‐100.0)        25.0 (19.4‐30.6)         43.8 (38.7‐48.8)    95.0 (92.8‐97.2)   1.30 (1.20‐1.41)      0.09 (0.03‐0.28)   14.78 (4.53‐48.23)
  ≤15 y                                                                                                                                                                                                 
  *C* ~los~                                     76.2 (68.0‐84.3)      76.8 (66.9‐86.8)         75.0 (60.9‐89.1)         85.5 (78.7‐92.2)    62.8 (53.5‐72.0)   3.07 (1.72‐5.49)      0.31 (0.19‐0.49)   9.94 (3.89‐25.41)
  ALP                                           61.0 (51.6‐70.3)      71.0 (60.3‐81.7)         41.7 (25.6‐57.8)         70.0 (61.2‐78.8)    42.9 (33.4‐52.3)   1.22 (0.89‐1.67)      0.70 (0.41‐1.19)   1.75 (0.75‐4.06)
  \>15 y                                                                                                                                                                                                
  *C* ~hos~                                     98.5 (97.0‐100.0)     94.0 (88.4‐99.7)         100.0                    100.0               98.0 (96.2‐99.7)   NA                    0.06 (0.02‐0.15)   NA
  ALP                                           81.5 (76.7‐86.2)      77.6 (67.6‐87.6)         82.8 (77.5‐88.1)         61.2 (55.2‐67.1)    91.4 (88.0‐94.8)   4.52 (3.23‐6.32)      0.27 (0.17‐0.42)   16.70 (8.41‐33.17)

Abbreviation: NA, not applicable.

John Wiley & Sons, Ltd

3.2. Performances of *C* ~os~, *C* ~los,~ and *C* ~hos~ to discriminate OS from primary benign bone lesions {#jcla23189-sec-0012}
-----------------------------------------------------------------------------------------------------------

It is also critical for clinical practice to differentiate OS and primary benign bone lesions, and a good OS classifier should be sufficiently sensitive and specific to exclude benign bone diseases. To validate whether our models can discriminate OS from primary benign bone lesions, 228 patients of eight primary benign bone lesions were used to test the prediction performance of the established OS classifiers. Basic demographics of each disease were listed in Table [S6](#jcla23189-sup-0005_TableS1-S10){ref-type="supplementary-material"}. These patients were also divided into two age groups: low ages (≤15 y) and high ages (\>15 y), and the age and gender of patients with OS and primary benign bone lesions were well matched in each group as well (Table [S7](#jcla23189-sup-0005_TableS1-S10){ref-type="supplementary-material"}).

Then, ROC analyses were performed, and the performances of *C* ~os~, *C* ~los,~ and *C* ~hos~ were compared with that of ALP. Although the sensitivity of ALP was higher than that of *C* ~os~ (97.8% vs 86.0%), *C* ~os~ was more accurate (87.6% vs 52.2%) and specific (88.6% vs 25.0%) to discriminate OS from primary benign bone lesions, and the AUC for *C* ~os~ was larger than that for ALP (0.96 vs 0.84) (Figure [2](#jcla23189-fig-0002){ref-type="fig"}D and Table [2](#jcla23189-tbl-0002){ref-type="table"}). In low ages, *C* ~los~ showed much greater performance than ALP, with larger AUC (0.84 vs 0.61), and higher accuracy (76.2% vs 61.0%), sensitivity (76.8% vs 71.0%), and specificity (75.0% vs 41.7%) (Figure [2](#jcla23189-fig-0002){ref-type="fig"}E and Table [2](#jcla23189-tbl-0002){ref-type="table"}). In addition, the performance of *C* ~hos~ in high ages was slightly better than that of ALP, and *C* ~hos~ had a larger AUC (1.00 vs 0.86) and higher accuracy (98.5% vs 81.5%), sensitivity (94.0% vs 77.6%), and specificity (100.0% vs 82.8%) compared to ALP as well (Figure [2](#jcla23189-fig-0002){ref-type="fig"}F and Table [2](#jcla23189-tbl-0002){ref-type="table"}). These data suggest that these established classifiers showed great performances to discriminate OS from primary benign bone lesions as well.

3.3. Performances of established classifiers to detect small‐size and early‐stage OS {#jcla23189-sec-0013}
------------------------------------------------------------------------------------

We next determined whether the established *C* ~os~, *C* ~los,~ and *C* ~hos~ were beneficial for early diagnosis of OS patients. ROC analyses were performed on small‐size (tumor size ≤ 6 cm) and early‐stage (clinical stage I‐II) OS in the validation cohort. For small‐size OS, *C* ~os~ identified small‐size tumors with larger AUC (0.93 vs 0.63), and higher accuracy (83.6% vs 57.2%), sensitivity (85.1% vs 62.7%), and specificity (82.6% vs 53.3%) in all ages (Figure [3](#jcla23189-fig-0003){ref-type="fig"}A, Table [3](#jcla23189-tbl-0003){ref-type="table"}). Similarly, *C* ~los~ had larger AUC (0.95 vs 0.65) to diagnose low age individuals with small‐size OS, and the accuracy (88.4%), sensitivity (94.1%), and specificity (84.6%) for *C* ~los~ were higher than those for ALP (accuracy 59.3%, sensitivity 70.6%, specificity 51.9%) as well (Figure [3](#jcla23189-fig-0003){ref-type="fig"}B, Table [3](#jcla23189-tbl-0003){ref-type="table"}). Although *C* ~hos~ was less specific than ALP (87.5% vs 90.0%) to distinguish patients with small‐size tumors from HCs in high ages, it still showed better performance than ALP with larger AUC (0.98 vs 0.76), and higher accuracy (90.4% vs 76.7%) and sensitivity (93.9% vs 60.6%) (Figure [3](#jcla23189-fig-0003){ref-type="fig"}C, Table [3](#jcla23189-tbl-0003){ref-type="table"}).

![Performance of *C* ~os~, *C* ~los,~ and *C* ~hos~ to detect small‐size and early‐stage osteosarcoma (OS). ROC curves from the validation cohort showed performance to distinguish individuals with small‐size OS (tumor size ≤ 6 cm) from healthy controls (HCs) in all ages (A), low ages (B), and high ages (C), respectively. Performance to distinguish individuals with early‐stage OS (clinical stage I‐II) from HCs in all ages (D), low ages (E), and high ages (F) was shown as well](JCLA-34-e23189-g003){#jcla23189-fig-0003}

###### 

Performance of *C* ~os~, *C* ~los~, *C* ~hos,~ and ALP to detect small‐size and early‐stage osteosarcoma

                      Accuracy % (95% CI)   Sensitivity % (95% CI)   Specificity % (95% CI)   PPV % (95% CI)      NPV % (95% CI)      PLR (95% CI)         NLR (95% CI)       DOR (95% CI)
  ------------------- --------------------- ------------------------ ------------------------ ------------------- ------------------- -------------------- ------------------ -----------------------
  Small‐size tumor                                                                                                                                                            
  All ages                                                                                                                                                                    
  *C* ~os~            83.6 (77.9‐89.4)      85.1 (76.5‐93.6)         82.6 (74.9‐90.4)         78.1 (71.7‐84.5)    88.4 (83.4‐93.4)    4.89 (3.10‐7.72)     0.18 (0.10‐0.32)   27.08 (11.44‐64.10)
  ALP                 57.2 (49.5‐64.9)      62.7 (51.1‐74.3)         53.3 (43.1‐63.5)         49.4 (41.6‐57.2)    66.2 (58.9‐73.6)    1.34 (1.01‐1.79)     0.70 (0.49‐1.01)   1.91 (1.01‐3.64)
  ≤15 y                                                                                                                                                                       
  *C* ~los~           88.4 (81.6‐95.1)      94.1 (86.2‐100.0)        84.6 (74.8‐94.4)         80.0 (71.5‐88.5)    95.7 (91.3‐100.0)   6.12 (3.22‐11.64)    0.07 (0.02‐0.27)   88.00 (17.50‐442.47)
  ALP                 59.3 (48.9‐69.7)      70.6 (55.3‐85.9)         51.9 (38.3‐65.5)         49.0 (38.4‐59.5)    73.0 (63.6‐82.4)    1.47 (1.03‐2.10)     0.57 (0.32‐1.01)   2.59 (1.04‐6.48)
  \>15 y                                                                                                                                                                      
  *C* ~hos~           90.4 (83.7‐97.2)      93.9 (85.8‐100.0)        87.5 (77.3‐97.7)         86.1 (78.2‐94.0)    94.6 (89.4‐99.8)    7.52 (3.30‐17.14)    0.07 (0.02‐0.27)   108.50 (19.63‐599.66)
  ALP                 76.7 (67.0‐86.4)      60.6 (43.9‐77.3)         90.0 (80.7‐99.3)         83.3 (74.8‐91.9)    73.5 (63.3‐83.6)    6.06 (2.30‐15.98)    0.44 (0.28‐0.68)   13.85 (3.98‐48.18)
  Early‐stage tumor                                                                                                                                                           
  All ages                                                                                                                                                                    
  *C* ~os~            84.9 (79.7‐90.0)      87.0 (80.4‐93.6)         82.4 (74.2‐90.5)         85.3 (80.2‐90.4)    84.3 (79.1‐89.6)    4.93 (3.10‐7.85)     0.16 (0.09‐0.26)   31.23 (13.94‐69.97)
  ALP                 60.0 (52.9‐67.1)      67.0 (57.8‐76.2)         51.8 (41.1‐62.4)         62.0 (55.0‐69.0)    57.1 (50.0‐64.3)    1.39 (1.07‐1.80)     0.64 (0.45‐0.90)   2.18 (1.20‐3.95)
  ≤15 y                                                                                                                                                                       
  *C* ~los~           89.1 (83.0‐95.2)      90.2 (82.0‐98.4)         88.0 (79.0‐97.0)         88.5 (82.2‐94.7)    89.8 (83.9‐95.7)    7.52 (3.53‐16.01)    0.11 (0.05‐0.26)   67.47 (19.20‐237.08)
  ALP                 59.4 (49.8‐69.0)      62.7 (49.5‐76.0)         56.0 (42.2‐69.8)         59.3 (49.7‐68.8)    59.6 (50.0‐69.1)    1.43 (0.98‐2.08)     0.67 (0.43‐1.03)   2.14 (0.97‐4.75)
  \>15 y                                                                                                                                                                      
  *C* ~hos~           91.7 (85.8‐97.6)      89.8 (81.3‐98.3)         94.3 (86.6‐100.0)        95.7 (91.3‐100.0)   86.8 (79.6‐94.1)    15.71 (4.08‐60.56)   0.11 (0.05‐0.25)   145.20 (26.50‐795.48)
  ALP                 79.8 (71.2‐88.4)      73.5 (61.1‐85.8)         88.6 (78.0‐99.1)         90.0 (83.6‐96.4)    70.5 (60.7‐80.2)    6.43 (2.52‐16.42)    0.30 (0.19‐0.48)   21.46 (6.34‐72.64)
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For early‐stage OS, *C* ~os~ had a larger AUC to identify all ages with early‐stage tumors (0.93 vs 0.65) with higher accuracy (84.9% vs 60.0%), sensitivity (87.0% vs 67.0%), and specificity (82.4% vs 51.8%) compared to ALP (Figure [3](#jcla23189-fig-0003){ref-type="fig"}D, Table [3](#jcla23189-tbl-0003){ref-type="table"}). Similarly, *C* ~los~ also showed better performance than ALP to detect early‐stage OS in low ages with larger AUC (0.96 vs 0.65), and higher accuracy (89.1% vs 59.4%), sensitivity (90.2% vs 62.7%), and specificity (88.0% vs 56.0%) (Figure [3](#jcla23189-fig-0003){ref-type="fig"}E, Table [3](#jcla23189-tbl-0003){ref-type="table"}). In addition, *C* ~hos~ was more sensitive (89.8% vs 73.5%) and specific (94.3% vs 88.6%) than ALP, with larger AUC (0.98 vs 0.83) and higher accuracy (91.7% vs 79.8%) to discriminate patients with early‐stage tumors from HCs in high ages (Figure [3](#jcla23189-fig-0003){ref-type="fig"}F, Table [3](#jcla23189-tbl-0003){ref-type="table"}). Collectively, these findings suggest that *C* ~os~, *C* ~los,~ and *C* ~hos~ have important clinical significance for the early diagnosis of OS.

3.4. Performances of *C* ~os~, *C* ~los,~ and *C* ~hos~ to detect ALP‐negative OS {#jcla23189-sec-0014}
---------------------------------------------------------------------------------

Over 40% of OS patients possessed normal/negative pre‐treatment serum ALP as described before. Next, to evaluate the diagnostic performances of *C* ~os~, *C* ~los,~ and *C* ~hos~ to identify ALP‐negative OS, ROC analyses were performed in the validation cohort as well. As shown in Figure [4](#jcla23189-fig-0004){ref-type="fig"}A and Table [4](#jcla23189-tbl-0004){ref-type="table"}, *C* ~os~ had a larger AUC to identify all ages with ALP‐negative tumors (0.91 vs 0.55) with higher accuracy (82.2% vs 52.8%), sensitivity (81.6% vs 53.9%), and specificity (82.8% vs 51.7%) compared to ALP. In low ages, *C* ~los~ had a great performance to detect ALP‐negative tumors with an AUC 0.96, and the accuracy, sensitivity, and specificity were 88.0%, 83.3%, and 92.3%, respectively, which was much higher than those for ALP (AUC 0.51, accuracy 52.0%, sensitivity 66.7%, and specificity 38.5%) (Figure [4](#jcla23189-fig-0004){ref-type="fig"}B and Table [4](#jcla23189-tbl-0004){ref-type="table"}). Although ALP had a same sensitivity as *C* ~hos~ (89.3% vs 89.3%) to diagnose ALP‐negative tumors in high ages, *C* ~hos~ was more accurate (88.9% vs 50.8%) and specific (88.6% vs 20.0%), and the AUC for *C* ~hos~ was a little larger than that for ALP (0.97 vs 0.65) (Figure [4](#jcla23189-fig-0004){ref-type="fig"}C and Table [4](#jcla23189-tbl-0004){ref-type="table"}). These results clearly demonstrate that these established classifiers showed much better performances than ALP on ALP‐negative OS detection.

![Performance of *C* ~os~, *C* ~los,~ and *C* ~hos~ to detect ALP‐negative osteosarcoma (OS). ROC curves from the validation cohort showed performance to distinguish individuals with ALP‐negative OS (serum ALP below the upper limit of the reference interval) from healthy controls (HCs) in all ages (A), low ages (B), and high ages (C), respectively](JCLA-34-e23189-g004){#jcla23189-fig-0004}
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Performance of *C* ~os~, *C* ~los~, *C* ~hos,~ and ALP to detect ALP‐negative osteosarcoma

              Accuracy % (95% CI)   Sensitivity % (95% CI)   Specificity % (95% CI)   PPV % (95% CI)     NPV % (95% CI)     PLR (95% CI)         NLR (95% CI)       DOR (95% CI)
  ----------- --------------------- ------------------------ ------------------------ ------------------ ------------------ -------------------- ------------------ ----------------------
  All ages                                                                                                                                                          
  *C* ~os~    82.2 (76.3‐88.1)      81.6 (72.9‐90.3)         82.8 (74.8‐90.7)         80.5 (74.4‐86.6)   83.7 (78.1‐89.4)   4.73 (2.95‐7.59)     0.22 (0.14‐0.36)   21.26 (9.52‐47.48)
  ALP         52.8 (45.1‐60.4)      53.9 (42.7‐65.2)         51.7 (41.2‐62.2)         49.4 (41.7‐57.1)   56.3 (48.6‐63.9)   1.12 (0.83‐1.51)     0.89 (0.65‐1.22)   1.26 (0.68‐2.33)
  ≤15 y                                                                                                                                                             
  *C* ~los~   88.0 (81.6‐94.4)      83.3 (72.8‐93.9)         92.3 (85.1‐99.6)         90.9 (85.3‐96.5)   85.7 (78.9‐92.6)   10.83 (4.19‐28.01)   0.18 (0.10‐0.34)   60.0 (16.82‐213.97)
  ALP         52.0 (42.2‐61.8)      66.7 (53.3‐80.0)         38.5 (25.2‐51.7)         50.0 (40.2‐59.8)   55.6 (45.8‐65.3)   1.08 (0.81‐1.45)     0.87 (0.51‐1.47)   1.25 (0.55‐2.84)
  \>15 y                                                                                                                                                            
  *C* ~hos~   88.9 (81.1‐96.6)      89.3 (77.8‐100.0)        88.6 (78.0‐99.1)         86.2 (77.7‐94.7)   91.2 (84.2‐98.2)   7.81 (3.08‐19.82)    0.12 (0.04‐0.35)   64.58 (13.21‐315.75)
  ALP         50.8 (38.4‐63.1)      89.3 (77.8‐100.0)        20.0 (6.7‐33.3)          47.2 (34.8‐59.5)   70.0 (58.7‐81.3)   1.12 (0.91‐1.38)     0.54 (0.15‐1.88)   2.08 (0.49‐8.94)
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4. DISCUSSION {#jcla23189-sec-0015}
=============

In this study, diagnostic classifiers for OS in different age groups were established with logistical regression model. Top ten clinical parameters in each weight ranking were included, respectively. All classifiers, including *C* ~os~, *C* ~los~, and *C* ~hos~, had higher sensitivity and specificity than ALP to distinguish individuals with OS from HCs. In addition, these classifiers could discriminate OS from primary benign bone lesions. Furthermore, *C* ~os~, *C* ~los~, and *C* ~hos~ had better performances than ALP to detect small‐size, early‐stage, and ALP‐negative OS. These findings highlight the potential of *C* ~os~, *C* ~los~, and *C* ~hos~ as biomarkers for OS diagnosis at early clinical stages.

Despite of the importance of early diagnosis of OS, there is still no effective method at present. Early signs and symptoms, such as pain and pathological fracture, are not specific for OS, often resulting in initial misdiagnosis and delayed correct treatment for several months.[17](#jcla23189-bib-0017){ref-type="ref"} Biopsy is the gold standard for definitive diagnosis of OS,[18](#jcla23189-bib-0018){ref-type="ref"} but it is invasive and costly and requires an experienced pathologist. Our findings suggest that *C* ~os~, *C* ~los~, and *C* ~hos~ are promising non‐invasive assessments for early diagnosis of OS with high sensitivity and specificity. Notably, the diagnostic performances of these classifiers to detect small‐size and large‐size tumors (Figure [3](#jcla23189-fig-0003){ref-type="fig"}, Table [3](#jcla23189-tbl-0003){ref-type="table"}, Figure [S2](#jcla23189-sup-0002){ref-type="supplementary-material"}, and Table [S8](#jcla23189-sup-0005_TableS1-S10){ref-type="supplementary-material"}), as well as their ability to detect early‐stage and late‐stage tumors (Figure [3](#jcla23189-fig-0003){ref-type="fig"}, Table [3](#jcla23189-tbl-0003){ref-type="table"}, Figure [S3](#jcla23189-sup-0003){ref-type="supplementary-material"}, and Table [S9](#jcla23189-sup-0005_TableS1-S10){ref-type="supplementary-material"}), were different from each other, suggesting their performances are associated with tumor size and stage. In addition, although all three classifiers showed high sensitivity and specificity, there was still a little difference between the performances of *C* ~os~ and *C* ~los~ for low ages, as well as those of *C* ~os~ and *C* ~hos~ for high ages, indicating that *C* ~os~ combined with *C* ~los~ or *C* ~hos~ might be better for OS diagnosis than a single one in clinical practice.

In this study, many parameters were found to be dysregulated in OS, including those included in the classifiers (Tables [S3‐S5](#jcla23189-sup-0005_TableS1-S10){ref-type="supplementary-material"}). Different clinical parameters were included in the classifiers for all, low, and high ages according to the weight ranking of all parameters in the corresponding age group. The difference in weight ranking might be due to the distinction of dysregulated parameter patterns in different age groups. In addition to ALP, many other parameters made big contributions to the classifiers as well. For example, the weights of LDH and MPV were only slightly lower than that of ALP in all ages, whereas those of GGT and ALB were close to that of ALP in low ages. Interestingly, the weight of ALP was only ranked sixth, behind HDL‐C, MPV, IP, ALB, and LY% in high ages. These suggested the necessity of parameter combination to better diagnose OS.

ALP is widely distributed, especially in bone and liver and can be released in the circulation.[19](#jcla23189-bib-0019){ref-type="ref"} Many pathological conditions, such as liver disease, bone disease, endocrine disease, neoplasia, and other disorders, result in increased serum ALP activity.[20](#jcla23189-bib-0020){ref-type="ref"}, [21](#jcla23189-bib-0021){ref-type="ref"} Therefore, the specificity of ALP was unsatisfactory for OS diagnosis. In addition, previous studies have described the low sensitivity of ALP to detect OS.[10](#jcla23189-bib-0010){ref-type="ref"}, [22](#jcla23189-bib-0022){ref-type="ref"}, [23](#jcla23189-bib-0023){ref-type="ref"} Consistently, our study discovered that ALP was less sensitive and specific than our established classifiers to distinguish all OS patients from HCs and patients with primary benign bone lesions. For small‐size and early‐stage tumors, the performance of ALP was also poorer than *C* ~os~, C~yos~, and C~oos~. This study also extended the previous literature and evaluated the diagnostic value of ALP for ALP‐negative OS patients. As expected, ALP has much worse performance than established classifiers to detect ALP‐negative OS patients. In contrast, the sensitivity and specificity of ALP to detect ALP‐positive OS were high in each age group (Figure [S4](#jcla23189-sup-0004){ref-type="supplementary-material"} and Table [S10](#jcla23189-sup-0005_TableS1-S10){ref-type="supplementary-material"}). Therefore, this study further confirms the limited value of ALP in OS diagnosis.

Some diagnostic classifiers for OS diagnosis have been established in previous studies. For example, metabolomic data were used to classify healthy individuals and patients with benign tumor or OS, and the established classifiers have good performances to distinguish tumors and healthy controls (largest AUC 0.99 for either training or testing set), whereas the performances to discriminate OS from benign tumor were poor (largest AUC 0.60 for either training or testing set).[24](#jcla23189-bib-0024){ref-type="ref"} Another study has also described a classifier established with integrative metabolomic and transcriptomic profiles, and the classifier had an AUC 0.83 to identify OS from healthy control.[25](#jcla23189-bib-0025){ref-type="ref"} In addition, a proteomic classifier was constructed with plasma proteomic profiles to distinguish OS from osteochondroma patients, and it achieved a high sensitivity (97%) and specificity (80%).[26](#jcla23189-bib-0026){ref-type="ref"} Compared with these studies, our research has several strengths. First, to guarantee the robustness of our conclusion, we recruited approximately 1000 participants, including patients with OS and benign bone lesions, as well as HCs, while the above studies included less than 100 samples separately. Second, both patients with different benign bone lesions and HCs were introduced as controls to assess the specificity of our classifiers, while some other studies included only HCs or benign tumors. Third, our classifiers were established with clinical parameters, which were widely used in clinic, while other classifiers were constructed with metabolomic, transcriptomic, or proteomic profiles, which required complex methods to acquire the data and were not suitable for clinical application at present.

Our study has a few limitations. First, there were only 46 hematological and biochemical parameters included in this study. Many other clinical parameters, such as C‐reactive protein, were not included, because it is not essential to test these parameters in routine medical examination, resulting in difficulty in data collection in the control group. Second, our participants were collected from only one clinical center in China and most cases of OS were Han Chinese. The study power might be increased when more clinical parameters and clinical centers are recruited to the retrospective study in the future, and the ability of *C* ~os~, C~yos~, and C~oos~ to detect OS in other ethnicities merits investigation.

In summary, our study suggests that our diagnostic classifiers could discriminate OS from HC and primary benign bone lesions effectively, and it is also valuable for identifying small‐size, early‐stage, and ALP‐negative OS with high sensitivity and specificity. The parameters included in the classifiers are routinely used in clinic, and the data are easy to acquire. Therefore, analysis of *C* ~os~, *C* ~los~, and *C* ~hos~ in clinical practice should be feasible.
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